Genetic evidence linking lung cancer and COPD: A new perspective

Application of Clinical Genetics

Volumn 4, Issue , 2011, Pages 99-111

  Young, Robert P ^a,d   Hopkins, Raewyn J ^a   Gamble, Gregory D ^a   Etzel, Carol ^b   El Zein, Randa ^b   Crapo, James D ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c DEPARTMENT OF MEDICINE   (United States)

^d Synergenz Biosciences Ltd   (New Zealand)

Author keywords

Association study; Chronic obstructive pulmonary disease; Lung cancer; Risk model; Single nucleotide polymorphism

Indexed keywords

CANCER RISK; CANCER SUSCEPTIBILITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; GENE FREQUENCY; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; LUNG CANCER; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

NICOTIANA TABACUM;

EID: 80054092274     PISSN: 1178704X     EISSN: None     Source Type: Journal    
DOI: 10.2147/TACG.S20083     Document Type: Review

References (88)

1. Broderick P, Wang Y, Vijayakarishnan V, et al. Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. Cancer Res. 2009;69:6633-6641.
2. Molfino NA. Genetics of COPD. Chest. 2004;125:1929-1940.
3. Witschi H. A short history of lung cancer. Toxicol Sci. 2001;64:4-6.
4. American Cancer Society. Available from: http://www.cancer.org/. Accessed July 26, 2010.
5. Mattson ME, Pollack ES, Cullen JW. What are the odds that smoking will kill you? Am J Pub Health. 1987;77:425-431.
6. Kohansal R, Martinez-Camblor P, Agusti A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham Offspring Cohort. Am J Respir Crit Care Med. 2009;180:3-10.
7. Løkke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax. 2006;61:935-939.
8. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark and Finland. N Engl J Med. 2000;343:78-85.
9. Hubert HB, Fabsitz RR, Feinleib M, Gwinn C. Genetic and environmental influences on pulmonary function in adult twins. Am Rev Respir Dis. 1982;125:409-415.
10. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD. COPD prevalence is increased in lung cancer independence of age, gender and smoking history. Eur Respir J. 2009;34: 380-386.
11. Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data from the first NHANES follow-up. Arch Intern Med. 2003;163:1475-1480.
12. Burrows B, Knudson RJ, Cline MG, Lebowitz MD. Qualitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis. 1977;115:195-205.
13. Dockery DW, Speizer FE, Ferris BG Jr, Ware JH, Louis TA, Spiro A. Cumulative and reversible effects of lifetime smoking on simple tests of lung function in adults. Am Rev Respir Dis. 1988;137:286-292.
14. Givelber RJ, Couropmitree NN, Gottlieb DJ, et al. Segregation analysis of pulmonary function among families in the Framingham study. Am J Respir Crit Care Med. 1998;157:1445-1451.
15. Young RP, Hopkins RJ, Eaton TE. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur Respir J. 2007;30:616-622.
16. Wilson DO, Weissfeld JL, Balkan A, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med. 2008;178:738-744.
17. Young R, Hopkins R. Lung function predicts lung cancer. Eur Respir J. 2010;35:1421-1422.
18. Sohal S, Reid D, Soltani A, et al. Reticular basement membrane fragmentation and potential epithelial mesenchymal transition is exaggerated in the airways of smokers with chronic obstructive pulmonary disease. Respirology. 2010;15:930-938.
19. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420-1428.
20. Dasari V, Gallup M, Lemjabbar H, Maltseva I, MacNarmara N. Epithelial-mesenchymal transition in lung cancer: is tobacco the "smoking gun"? Am J Respir Cell Mol Biol. 2006;35:3-9.
21. Shintani Y, Maeda M, Chaika N, Johnson KR, Wheelock MJ. Collagen 1 promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-β signalling. Am J Respir Cell Mol Biol. 2008;38:95-104.
22. Wilk J, Walter R, Laramie J, Gottlieb DJ, O'Connor GT. Framingham Heart Study genome-wide association: results for pulmonary function measures. BMC Med Genet. 2007;8(Suppl 1):S8.
23. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet. 2008;40:616-622.
24. Hancock DB, Eijgelsheim M, Wilk JB, et al. Meta-analyses of genomewide association studies identify multiple loci associated with pulmonary function. Nat Genet. 2009;42:45-52.
25. Repapi E, Sayers I, Wain LV, et al. Genome-wide association study identifies five loci associated with lung function. Nat Genet. 2009;42: 36-44.
26. Pillai SG, Ge D, Zhu G, et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet. 2009;5:e1000421.
27. Wilk JB, Chen T, Gottlieb DJ, et al. A genome-wide association study of pulmonary function measures in the Framingham Heart Study. PLoS Genet. 2009;5:e1000429.
28. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452:633-637.
29. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452:638-642.
30. Young RP, Hopkins RJ, Hay BA, Epton MJ, Black PN, Gamble GD. Lung cancer gene associated with COPD: triple whammy or possible confounding effect? Eur Respir J. 2008;32:1-7.
31. Young RP, Whittington CF, Hopkins RJ, et al. Chromosome 4q31 locus in COPD also associated with lung cancer. Eur Respir J. 2010;36;1375-1382.
32. Young RP, Hopkins RJ, Hay BA, et al. FAM13A locus in COPD independently associated with lung cancer - evidence of a molecular genetic link between COPD and lung cancer. Appl Clin Genet. 2011;4:1-10.
33. Gwilt CR, Donnelly LE, Rogers DF. The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation? Pharmacol Ther. 2007;115:208-222.
34. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature. 2003;422:313-317.
35. Richens TR, Linderman DJ, Horstmann SA, et al. Cigarette smoke impairs clearance of apoptotic cells through oxidant-dependent activation of Rho A. Am J Respir Crit Care Med. 2009;179:1011-1021.
36. Asnaghi L, Vass WC, Quadri R, et al. E-Cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of GTPases. Oncogene. 2010;29:2760-2771.
37. Young RP, Hopkins R, Eaton TE. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev. 2009;18:222-232.
38. Petty TL. Are COPD and lung cancer two manifestations of the same disease? Chest. 2005;128:1895-1897.
39. Schwartz AG, Ruckdeschel JC. Familial lung cancer: genetic susceptibility and relationship to chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173:16-22.
40. Young RP, Hopkins RJ, Hay BA, et al. A gene based risk score for lung cancer susceptibility in smokers and ex-smokers. Postgrad Med J. 2009;85:515-524.
41. Punturieri A, Szabo E, Croxton TL, Shapiro SD, Dubinett SM. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst. 2009;101:554-559.
42. Frayling TM. Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet. 2007;8:657-662.
43. Young RP, Hopkins RJ. Link between COPD and lung cancer. Respir Med. 2010;104:758-759.
44. Young RP, Hopkins RJ, Whittington CF, et al. Individual and cumulative effects of GWAS loci in lung cancer: associations after sub-phenotyping for COPD. PLoS One. 2011;6:e16476.
45. Stav D, Raz M. Prevalence of chronic obstructive pulmonary disease among smokers aged 45 and up in Israel. Isr Med Assoc J. 2007;9:800-802.
46. Zaas D, Wise R, Wiener C, et al. Airways obstruction is common but unsuspected in patients admitted to a general medicine service. Chest. 2004;125:106-111.
47. Hill K, Goldstein RS, Guyatt GH, et al. Prevalence and under-diagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ. 2010;182:673-678.
48. Koshiol J, Rotunno M, Consonni D, et al. Chronic obstructive pulmonary disease and altered risk of lung cancer in a population-based case-control study. Plos One. 2009;4:e7380.
49. Yang P, Yafei L, Jiang R, Cunningham JM, Zhang F, de Andrade M. A rigorous and comprehensive validation: common genetic variations and lung cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:240-244.
50. Lambrechts D, Buysschaert I, Zanen P, et al. The 15q24/25 susceptibility variant for lung cancer and chronic obstructive pulmonary disease is associated with emphysema. Am J Respir Crit Care Med. 2010;181:486-493.
51. Wang J, Spitz MR, Amos CI, et al. Mediating effects of smoking and chronic obstructive pulmonary disease on the relation between the CHRNA5-A3 genetic locus and lung cancer. Cancer. 2010; 116:3458-3462.
52. Cho MH, Boutaoui N, Klanderman BJ, et al. Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet. 2010;42:200-202.
53. Janssens ACJW, van Duijn CM. Genome-based prediction of common disease: methodological considerations for future research. Genome Med. 2010;1:20.
54. Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA. 2008;299:1335-1344.
55. Piitulainen E, Eriksson S. Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ). Eur Respir J. 1999;13:247-251.
56. Vilkman S, Keistinen T, Tuuponen T, Kivela SL. Survival and cause of death among elderly chronic obstructive pulmonary disease patients after first admission to hospital. Respiration. 1997;64:281-284.
57. Marciniak SJ, Lomas DA. What can naturally occurring mutations tell us about the pathogenesis of COPD. Thorax. 2009;64:359-364.
58. Young RP, Hopkins R, Black PN, et al. Functional variants of antioxidant genes in smokers with COPD and in those with normal lung function. Thorax. 2006;30:394-399.
59. Li Y, Sheu CC, Ye YQ, et al. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol. 2010;11:321-330.
60. Sampsonas F, Kaparianos A, Lykouras D, Karkoulias K, Spiropoulos K. DNA sequence variations of metalloproteinases: their role in asthma and COPD. Postgrad Med J. 2007;83:244-250.
61. Moskvina V, Holmans P, Schmidt KM, Craddock N. Design of case-controls studies with unscreened controls. Ann Hum Genet. 2005;68:566-576.
62. Sin DD, Leipsic J, Man SFP. CT in COPD: just a pretty picture or really worth a thousand words (or dollars)? Thorax. May 19, 2011. [Epub ahead of print].
63. Tockman MS, Anthonisen N, Wright EC, Donithan MG. Airways obstruction and the risk for lung cancer. Ann Intern Med. 1987; 106:512-518.
64. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of smoking cessation intervention on 14.5 year mortality: a randomized clinical trial. Ann Intern Med. 2005; 142:233-239.
65. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000;321:323-329.
66. McBride CM, Bepler G, Lipkus IM, et al. Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income. Cancer Epidemiol Biomarkers Prev. 2002;11:521-528.
67. Carpenter MJ, Strange C, Jones Y, et al. Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. Ann Behav Med. 2007;33:22-28.
68. Bach PB. Lung cancer assessment tool. Available from: http://www.mskcc.org. Accessed June 15, 2011.
69. Cassidy A, Duffy SW, Myles JP, Liloglou T, Field JK. Lung cancer risk prediction: a tool for early detection. Int J Cancer. 2006;120:1-6.
70. Spitz MR, Hong WK, Amos CI, et al. A risk model for prediction of lung cancer. J Nat Cancer Inst. 2007;99:715-726.
71. Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008;358:910-919.
72. Wright CF, Kroese M. Evaluation of genetic tests for susceptibility to complex diseases: why, when and how? Hum Genet. 2010; 127:125-134.
73. Meigs JB, Shrader P, Sullivan LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med. 2008;359:2208-2219.
74. He M, Cornelis MC, Franks PW, Zhang C, Hu FB, Qi L. Obesity, genotype score and cardiovascular risk in women with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2010;30:327-333.
75. Spitz MR, Amos CI, D'Amellio, Dong Q, Etzel C. Re: discriminatory accuracy from single-nucleotide polymorphisms in models. J Natl Cancer Inst. 2009;24:1731-1732.
76. Young RP, Hopkins RJ, Hay BJ, Gamble GD. GWAS and candidate SNPs for COPD and lung cancer combine to identify lung cancer susceptibility: validation in a prospective study. Abstr A3738 presented at the annual meeting of the American Thoracic Society, New Orleans, LA, May 14-19, 2010.
77. Thankkinstian A, Thompson JR, Minelli C, Attia J. Choosing between per-genotype, per-allele, and trend approaches for initial detection of gene-disease association. J Appl Stat. 2009;36:633-646.
78. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348:529-537.
79. Smith SM, Campbell NC, MacLeod U, et al. Factors contributing to the time taken to consult with symptoms of lung cancer: a cross-sectional study. Thorax. 2009;64:523-531.
80. Wald NJ. When can a risk factor be used as a worthwhile screening test? BMJ. 1999;319:1562-1565.
81. Young RP, Hopkins RJ, Smith M, Hogarth DK. Smoking cessation: the potential role of risk assessment tools as motivational triggers. Postgrad Med J. 2010;86:26-33.
82. Hopkins RJ, Young RP, Hay BA, Gamble GD. Gene-based risk test for lung cancer risk motivates smoking cessation in randomly selected smokers. Abstr P4714 presented at the annual meeting of the European Respiratory Society, Barcelona, Spain, September 18-22, 2010.
83. Collins FS. Shattuck lecture - Medical and societal consequences of the human genome project. N Engl J Med. 1999;341:28-37.
84. Bechtel JJ, Kelly WA, Coons TA, et al. Lung cancer detection in patients with airflow obstruction identified in a primary care outpatient practice. Chest. 2005;127:114-115.
85. Lee G, Walser TC, Dubinett SM. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr Opin Pulm Med. 2009;15:303-307.
86. Young RP, Hopkins RJ, Field JK, et al. Gene-based lung cancer risk test identifies smokers for early detection of lung cancer. Abstr B31 presented at the annual meeting of the American Association of Cancer Research, Frontiers in the Prevention of Cancer, Philadelphia, PA, November 7-10, 2010.
87. Kolor K, Liu T, St Pierre J, Khoury MJ. Health care provider and consumer awareness, perceptions and use of direct to consumer personalgenomic tests, US, 2008. Genet Med. 2009;11:595.
88. You M, Wang D, Liu P, et al. Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clin Cancer Res. 2009;15:2666-2674.